Global longitudinal strain, myocardial storage and hypertrophy in Fabry disease

Ravi Vijapurapu,1,2 Sabrina Nordin,3 Shanat Baig,1,2 Boyang Liu,1,2 Stefania Rosmini,3 Joao Augusto,3 Michel Tchan,1 Derralynn A Hughes,5 Tarekegn Geberhiwot,6 James C Moon,3 Richard Paul Steeds,1,2 Rebecca Kozor4

ABSTRACT

Introduction Detecting early cardiac involvement in Fabry disease (FD) is important because therapy may alter disease progression. Cardiovascular magnetic resonance (CMR) can detect T1 lowering, representing myocardial sphingolipid storage. In many diseases, early mechanical dysfunction may be detected by abnormal global longitudinal strain (GLS). We explored the relationship of early mechanical dysfunction and sphingolipid deposition in FD.

Methods An observational study of 221 FD and 77 healthy volunteers (HVs) who underwent CMR (LV volumes, mass, native T1, GLS, late gadolinium enhancement, ECG and blood biomarkers, as part of the prospective multicentre Fabry400 study.

Results All FD had normal LV ejection fraction (EF 73%±8%). Mean indexed LV mass (LVM) was 98±39 g/m² in FD and 55.6±10 g/m² in HV. 102 (46%) FD participants had left ventricular hypertrophy (LVH). There was a negative correlation between GLS and native T1 in FD patients (r=−0.515, p<0.001). In FD patients without LVH (early disease), as native T1 reduced there was impairment in GLS (r=−0.285, p<0.002). In the total FD cohort, ECG abnormalities were associated with a significant impairment in GLS compared with those without ECG abnormalities (abnormal: −16.7±3.5 vs normal: −30±2.4, p<0.001).

Conclusions GLS in FD correlates with an increase in LVMi, storage and the presence of ECG abnormalities. In LVH-negative FD (early disease), impairment in GLS is associated with a reduction in native T1, suggesting that mechanical dysfunction occurs before evidence of sphingolipid deposition (low T1).

Trial registration number NCT03199001; Results.

INTRODUCTION

Fabry disease (FD) is a X-linked lysosomal storage disorder caused by mutations in the gene (GLA) encoding for α-galactosidase A. The progressive accumulation of complex sphingolipids, predominantly globotriaosylceramide1 affects multiple organs, including the heart where it results in left ventricular hypertrophy (LVH), progressive cardiomyopathy, myocardial fibrosis and arrhythmias.2 Cardiac involvement is a major contributor to morbidity and mortality in FD.3 Evidence suggests that best outcomes may occur with early initiation of enzyme replacement therapy (ERT).4 Early cardiac involvement is difficult to detect and the identification of early phenotypic markers is required. Change in myocardial deformation—systolic strain—also offers potential of earlier disease detection. Impairment of global longitudinal strain (GLS) has been described in FD using speckle tracking echocardiography in those with and without LVH.3,5 Impaired GLS precedes any reduction in ejection fraction and is linked to worse functional status.6 Cardiovascular magnetic resonance (CMR) with T1 mapping has provided important insights into FD. T1 mapping is based on the magnetic resonance rate constant T1 (measured in milliseconds) that alters depending on changes in tissue characteristics; for example, fibrosis, oedema and amyloid increase T1, and iron and fat decrease T1. Low native T1 values (prior to contrast administration) are postulated to indicate sphingolipid accumulation in FD and occur in up to 59% of LVH-negative FD patients.7 CMR imaging can also quantify myocardial strain using feature-tracking (FT-CMR) but there is a paucity of knowledge regarding its application in FD. We aimed to determine whether early storage (low T1 measured using T1 mapping) would alter myocardial contractility (measured using FT-CMR) before the development of LV hypertrophy. Additionally, we aimed to evaluate if electrical abnormalities (detected on the 12-lead ECG) alter with cardiac contractility during this earlier phase of the disease process.

METHODS

Study population

Participants were recruited from four Fabry clinics as part of the prospective, multicentre international observational Fabry400 study (NCT03199001)—UK: Royal Free Hospital London, National Hospital for Neurology and Neurosurgery London, Queen Elizabeth Hospital Birmingham; Australia: Westmead Hospital Sydney. Inclusion criteria for the FD cohort included gene-positive FD and adults≥18 years. The healthy volunteer controls (HVs) were prospectively recruited and had no history of cardiovascular disease (normal health questionnaire, no cardiovascular active medication unless for primary prevention). Exclusion criteria included standard contraindications to CMR. All participants underwent CMR, ECG and blood samples during the same study visit. High-sensitivity cardiac troponin T (UK) and I (Australia) (hs-TnT and hsTnI) was measured using an electrochemiluminescence-immunoassay (Roche, Basel, Switzerland; normal range 0–14 ng/L and 0–15 ng/L, respectively).

Check for updates

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Vijapurapu R, Nordin S, Baig S, et al. Heart 2019;105:470–476.
CMR imaging
All participants underwent CMR at 1.5 T (Avanto (UK), Aera (Australia); Siemens Healthcare, Erlangen, Germany) using a standard protocol including LV cines in short axis (SAX), four-chamber, two-chamber and three-chamber views. Native T1 mapping was performed pre-contrast on basal and mid-left ventricular SAX slices using a shortened modified Look-Locker inversion recovery (ShMOLLI) sequence.10 The resulting pixel-by-pixel T1 colour maps were displayed using a customised 12-bit lookup table, where normal myocardium was green, increasing T1 was red and decreasing T1 was blue. Late gadolinium enhancement (LGE) imaging was performed using phase sensitive inversion recovery (bolus administration of gadolinium 0.1 mmol/kg bodyweight, Gadoterate meglumine, Dotarem, Guerbet S.A., France)

CMR analysis
All images were centralised and analysed using CVI42 software (Circle Cardiovascular Imaging, Calgary, Canada). Cardiac chamber volumes and LV mass (LVM) (papillary muscles included in mass) were quantified on all subjects from a pre-con-trast breath-held SAX stack of balanced steady-state free preces-sion cine images using previously described manual contouring methodologies.11 LVH was defined as increased indexed LVM on CMR according to age and gender-matched normal reference ranges.12 Maximum wall thickness (MWT) was evaluated using semi-automated measurement on CVI42 software and a value >12 mm was classified as being LVH positive.

Strain
Analysis of 2D GLS was obtained using CVI42 V.5.3.4. Smooth epicardial and endocardial borders were manually drawn on the end-diastolic frame of all long axis images (four-chamber, two-chamber and three-chamber views), and then strain (peak GLS, the most negative value during systole) was obtained from the applied automatic FT algorithm (eg, figure 1A). FT evaluates myocardial strain by using a deformable 2D model and translating this onto all 2D cine slices selected over the entirety of the cardiac cycle. The extent of deformation is determined by motion of an imaginary line placed between endocardial and epicardial boundaries, which are tracked throughout the cardiac cycle by a predetermined algorithm as previously described.13 14 The accuracy of FT was confirmed manually for each case (by RV), and to ensure reproducibility a maximum of five operator corrections were performed.

Intraobserver reproducibility was performed by observer 1 (RV) carrying out CMR reanalysis in random subset of 30 study patients. For interobserver variability, observer 2 (BL) independently analysed a randomly determined subset of 20 CMR scans.

Native T1
Visual inspection of T1 colour maps has shown sphingolipid deposition to be variable within the myocardium, and consequently four regions of interest (ROIs) were drawn in the septal and lateral LV wall at basal and mid cavity level, taking care to avoid the blood–myocardial boundary15 (eg, figure 1B). Since T1 is known to vary between field strength, acquisition tech-nique and site, and gender (females typically have higher T1 than males),13 the normal ranges of T1 values were defined as mean ±2SDs based on site-specific healthy controls from each individual centre (London: males mean 956±27 ms, lower limit 902 ms; females mean 978±34 ms, lower limit 910 ms. Birmingham: males mean 947±28 ms, lower limit 890 ms; females mean 958±30 ms, lower limit 898 ms. Sydney: males mean 947±24 ms, lower limit 893 ms; females mean 965±31 ms, lower limit 903 ms).

ECG
Abnormal ECGs included the presence of any irregularities (prolonged or shortened PR interval, QRS duration >120 ms, the presence of LVH by Cornell voltage criteria, T wave inversion in at least two contiguous leads or the presence of ventricular ectopy).

Statistical analysis
Statistical analyses were carried out using SPSS V.22 (IBM). Continuous variables are expressed as mean ±SD, categorical as frequen-cies or percentages. Normality was checked using the Shapiro-Wilk test. Groups were compared using the independent-samples t-test (normally distributed variables) or the Mann-Whitney U test (non-normally distributed). χ2 testing was used when comparing proportions of a variable between two groups. Troponin values were analysed after log transformation using parametric testing. Linear regression analysis (stepwise backward method) was used to evaluate the relationship between multiple variables and the study outcome. Comparisons of GLS across groups of gender and T1 were assessed using an analysis of variance (ANOVA) model with post-hoc Tukey correction. A similar approach was used to assess the relationship between T1 and GLS in the LVH-negative and LVH-positive groups, which included three terms, namely the two factors and an interaction between them. Goodness of fit of ANOVA and regression models was assessed by visual inspection of the residuals of the model, to ensure normality.

A p value of <0.05 was considered statistically significant. Intraobserver and interobserver reproducibility was determined by calculating mean bias and 95% CIs using Bland-Altman analyses and intraclass correlation coefficient (ICC) for absolute agreement.

RESULTS
Participant characteristics
There were 298 participants in total (221 FD and 77 HV). This included 155 from London, 37 from Birmingham and 29 from...
Sydney. Baseline demographics are demonstrated in table 1. The mean FD age was 45±15 years with 85 males (38.5%) and 136 females (61.5%). The HV population was age-matched (±2 years) with a mean age of 49.4±15 years (males 51.9%). All FD had normal LVEF (73%±8.0%). Mean indexed LV mass (LVMi) was 89.0±39 g/m² in FD and 55.6±10 g/m² in HV. MWT was significantly higher in FD compared with HV (12±5.0 mm vs. 9±1.6 mm, respectively, p<0.01). There was significant correlation between LVMi and MWT in both groups (FD: r=0.9 and HV: r=0.7, p<0.001). 70.8% of patients had a classical mutation and the remaining 29.2% non-classical. There were 102 (46%) FD participants with LVH.

Global myocardial strain
Adequate tracking quality was obtained for all study participants. Left ventricular ejection fraction (LVEF) did not correlate with LVMi (r=0.004, p=0.9). However, GLS became increasingly impaired (values becoming less negative) as LVMi increased (r=0.728, p<0.001; figure 2A,B). GLS was impaired in the LVH-positive FD group compared with LVH-negatives and HV (table 2, p<0.05). This was similar when split by sex; however, the difference was greater in the male cohort (table 2). Similar relationships were observed when correlating LVEF and GLS with MWT as a marker of myocardial hypertrophy (online supplementary table 1).

Myocardial native T1 and strain
In the total FD cohort, 72% (n=159/221) had a low native T1~91% in the LVH-positive subgroup (n=93/102) compared with 56% in the LVH-negative subgroup (n=66/119). There was significant negative correlation between GLS and native T1 in the total FD cohort (r=−0.515, p<0.05) as shown in figure 3A.

*P value is for Fabry male-to-female comparisons.
DBP: diastolic blood pressure; HR: heart rate; GLS: global longitudinal strain; LGE: late gadolinium enhancement; LVH: left ventricular hypertrophy; LVEF: left ventricular ejection fraction; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; LVMi: indexed left ventricular mass; MWT: maximum wall thickness; NS: non-significant; SBP: systolic blood pressure; BSA: body surface area.

### Table 1: Participant demographics and basic cardiovascular magnetic resonance findings

|                           | Healthy volunteers | Fabry total | Fabry males | Fabry females | P values |
|---------------------------|------------------|-------------|-------------|--------------|----------|
| Sample size (n, %)        | 77 (100)         | 221 (100)   | 85 (38.5)   | 136 (61.5)   | –        |
| Age (years)               | 49.4±14.4        | 45.1±5.0    | 45±14.8     | 44±15.3      | NS       |
| HR (bpm)                  | 65.4±9           | 62.1±12     | 59.1±12     | 64±12        | <0.05    |
| SBP (mm Hg)               | 122±13           | 120±17      | 125±16      | 118±17       | <0.05    |
| DBP (mm Hg)               | 76±9             | 73±10       | 74±12       | 72±9         | NS       |
| BSA (m²)                  | 1.9±0.2          | 1.8±0.2     | 1.9±0.2     | 1.7±0.2      | <0.05    |
| LVEF (%)                  | 70.2±5.6         | 73.±8.0     | 71±9.0      | 74±7.2       | <0.05    |
| LVEDV (ml)                | 132.1±28.4       | 131±31.7    | 146±37.3    | 121±22.7     | <0.05    |
| LVESV (ml)                | 39.6±11.9        | 36±17.1     | 43±21.0     | 32±12.6      | <0.05    |
| GLS                       | −19.3±2.0        | −18.5±3.6   | −16.3±3.3   | −19.9±3.0    | <0.05    |
| Native T1 (ms)            | 955.2±29.9       | 879±64.3    | 838.8±51.5  | 904.6±58.4   | <0.05    |
| LGE (n, %)                | 0 (0)            | 77 (100)    | 36 (46.8)   | 41 (53.2)    | <0.05    |
| LVH-positive (n, %)       | 0 (0)            | 102 (100)   | 63 (61.8)   | 39 (38.2)    | <0.05    |
| LVMi (g/m²)               | 55.6±10.1        | 89±39.3     | 116±42.6    | 71±24.9      | <0.05    |
| MWT (mm)                  | 9±1.6            | 12±5.0      | 15±5.1      | 10±3.8       | <0.05    |

*Figure 2 Scatter plots showing the relationship between indexed left ventricular (LV) mass and LV functional markers in the total Fabry cohort (males and females). (A) No correlation between left ventricular ejection fraction (LVEF) and indexed left ventricular mass (LVMi) and (B) significant positive correlation between LVMi and global longitudinal strain (GLS), suggesting this is a more sensitive functional marker, NS, non-significant.
Table 2  Mean global longitudinal strain values in various subcohorts of the total study population

| Study population | Healthy volunteers | Fabry disease | P values |
|------------------|--------------------|---------------|----------|
|                  | N      | Mean±SD  | N      | Mean ± SD |         |
| Total            | 77     | −19.3±2.0 | 221    | −18.5±3.6 | 0.02    |
| Male             | 40     | −18.5±1.8 | 85     | −16.4±3.3 | 0.001   |
| Female           | 37     | −20.2±1.9 | 136    | −19.9±3.0 | 0.46    |
| LVH positive     |        |          |        |          |         |
| Total            | 102    | −16.4±3.6 |        |          | 0.001   |
| Male             | 63     | −15.5±3.4 |        |          | 0.001   |
| Female           | 39     | −17.8±3.5 |        |          | 0.001   |
| LVH negative     |        |          |        |          |         |
| Total            | 119    | −20.3±2.6 |        |          | 0.001   |
| Male             | 22     | −18.3±1.6 |        |          | 0.62    |
| Female           | 97     | −20.9±2.5 |        |          | 0.19    |

*P values are comparing Fabry to healthy volunteers in all groups.

LVH-negative FD population

There were 119 FD participants who were LVH negative when classified by LVMi (53.8% of total FD population). The mean age was 37±13.4 years, which was significantly lower than the LVH-positive group (53±11.7 years, p<0.05). 81.5% of the LVH negative cohort were female and 68.6% had a classical mutation. Mean LVMi was higher in this group than in HV (62±10.4 g/m² vs 55.6±10.1 g/m², p<0.05), but maximum wall thickness (MWT) was similar (8.8±1.7 mm vs 9.0±1.6 mm, p=0.5). GLS in LVH-negative FD was better (more negative) compared with HV (−20.3±2.9 and −19.3±2.0, p<0.05). When split by sex, however, no significant differences were seen compared with age-matched HV (table 2).

In the LVH-negative FD subgroup, as native T1 reduced there was also impairment in GLS (r=−0.285, p<0.002) as shown in figure 3B. This gradient was not found to differ significantly between LVH-negative and LVH-positive FD (interaction term: p=0.137), with significant correlations between GLS and native T1 detected in both groups (r=−0.285 and −0.326, respectively, p<0.002 for both). When split by sex, LVH-negative males demonstrated a greater tendency towards impairment in GLS as native T1 reduced compared with those LVH-negative with normal T1 (figure 4, table 3); however, due to a low number of males who were LVH negative with a normal T1 (n=5), this was not significant. When classifying LVH using MWT, similar significant trends were observed (online supplementary figure 1 and table 2).

Multivariable linear regression analysis demonstrated that LVMi and the presence of ECG abnormalities were both independent predictors of a reduction in GLS. Further regression
Heart failure and cardiomyopathies

### Table 3  Mean global longitudinal strain values in the left ventricular hypertrophy-negative Fabry population classified according to native T1 compared with healthy volunteers

|                | Healthy volunteers | Fabry disease |                      |                      |
|----------------|--------------------|---------------|----------------------|----------------------|
|                | N                  | Normal T1     | Low T1               |                      |
|                | Mean±SD            | N Mean±SD     | N Mean±SD            |                      |
| Total          | 77                 | −19.3±2.0     | 53 −20.5±1.9         | 66 −20.2±2.6         |
| Male           | 40                 | −18.5±1.8     | 5 −20.0±1.0          | 17 −18.3±1.6         |
| Female         | 37                 | −20.2±1.9     | 48 −20.6±2.0         | 49 −20.9±2.5         |

P values from ANOVA

Male: p=0.152  Female: p = 0.329

This table shows mean±SD values for global longitudinal strain. P values are from an analysis of variance (ANOVA) model with post-hoc Tukey correction.

### Table 4  Mean global longitudinal strain values in the left ventricular hypertrophy (LVH)-positive and LVH-negative Fabry subgroups classified according to ECG abnormalities

|                | ECG normal | ECG abnormal |
|----------------|------------|--------------|
|                | N          | Mean±SD      | N          | Mean±SD    | P values |
| Total cohort   |            |              |            |            |          |
| Fabry total    | 204        | −20.2±2.4    | 92         | −16.7±3.5  | <0.001   |
| Male           | 77         | −18.4±2.0    | 48         | −15.6±3.1  | <0.001   |
| Female         | 127        | −20.8±2.2    | 44         | −18.0±3.6  | <0.001   |
| LVH positive   |            |              |            |            |          |
| Fabry total    | 93         | −18.7±2.6    | 70         | −15.9±3.4  | <0.001   |
| Male           | 56         | −17.8±2.2    | 43         | −15.2±3.1  | 0.006    |
| Female         | 37         | −19.9±2.7    | 27         | −17.0±3.7  | 0.03     |
| LVH negative   |            |              |            |            |          |
| Fabry total    | 111        | −20.6±2.2    | 22         | −19.3±2.6  | 0.02     |
| Male           | 21         | −18.8±1.8    | 5          | −18.7±0.5  | 0.80     |
| Female         | 90         | −21.0±2.1    | 17         | −19.5±3.0  | 0.02     |

P values are comparing ECG normal vs ECG abnormal in all groups and are taken from an independent t-test evaluating the LVH-positive and LVH-negative groups in separate t-test models.

### Discussion

The main findings of this study include

1. Impaired GLS occurs in FD in the absence of reduced LVEF. The impairment in deformation is proportionate to an increase in LVM and storage (as reflected by low T1).

### ECG

An abnormal ECG was found in 45.1% of the FD cohort. The frequency of ECG abnormalities was greater in the LVH-positive cohort compared with the LVH-negative group (75.2% vs 24.7%, respectively). In the total Fabry cohort, ECG abnormalities were associated with a significant impairment in GLS compared with those without ECG abnormalities (abnormal: −16.7±3.5 vs normal: −20.2±2.4, p<0.001). When evaluating the LVH-positive cohort, this same relationship was observed in both males and females. However, in the LVH-negative cohort, only females and not males had a significant difference in GLS with ECG abnormalities (table 4).

### Biomarkers

Of the FD population, 156 (70.6%) had high-sensitivity troponin measured (hsTnT or hsTnl), with 27.6% having an elevated level above centre-specific reference ranges. Median troponin in the total study population was 6.0 μg/L (IQR 1–31 μg/L). An increasing level of troponin was associated with impairment in GLS in the total FD population (r=0.516, p<0.05). Of the LVH-negative population, 87 patients (73.1%) had hsTnT or hsTnl measured and only 5 had an elevated serum level with all others having a value <5 μg/L. No significant relationship was demonstrated between strain and troponin in the LVH-negative group (r=0.169, p=0.118).

### Reproducibility

Intraobserver reproducibility analysis performed following repeat evaluation of 30 CMR scans by observer 1 (RV) demonstrated a mean absolute bias of 0.7±0.6 with an ICC for single measures of 0.98 (95% CI 0.96 to 0.99). Reproducibility biases were similar when assessing interobserver reproducibility following analysis of a subset of 20 CMR scans by observer 2 (BL)—mean absolute bias 0.6±0.5 and ICC for single measures of 0.99 (95% CI 0.97 to 1.0).

### Late gadolinium enhancement

In total, 183 participants were given gadolinium-based contrast agents, and of these 77 (34.8%) had LGE. There was a significant difference in mean GLS between FD with and without LGE (LGE: −17.1±3.7 vs no LGE: −19.7±2.9, p<0.05). In the LVH-negative group, there were 14 out of 84 participants who had LGE (16.7%, all females) and there was no change in mean GLS measured (LGE: −20.4±2.2 vs no LGE: −20.1±2.2 vs HV: 19.3±2.0, p=0.6).

### Analysis

Analysis also demonstrated that LVMi and GLS were predictors of native T1. This was true in both the total population and the LVH-negative cohort (online supplementary table 3).

### Enzyme replacement therapy

Of the total FD cohort, 54.3% were on ERT and there was a significant difference in peak GLS in those taking ERT compared with those not on therapy (on ERT vs ERT naive: −17.6±3.8 vs −19.7±2.9, p<0.01). When split by sex, this difference was only present in the female population (female: on ERT −19.2±3.5 vs ERT naive −20.4±2.5, p<0.05; male: on ERT −16.2±3.5 vs ERT naive −16.9±2.5, p=NS). Of the LVH-negative cohort, 36.1% were on ERT; however, no significant differences in GLS were seen compared with those not on ERT.

### Late gadolinium enhancement

In total, 183 participants were given gadolinium-based contrast agents, and of these 77 (34.8%) had LGE. There was a significant difference in mean GLS between FD with and without LGE (LGE: −17.1±3.7 vs no LGE: −19.7±2.5, p<0.05; LGE: −17.1±3.7 vs HV: 19.3±2.0, p<0.05). In the LVH-negative group, there were 14 out of 84 participants who had LGE (16.7%, all females) and there was no change in mean GLS measured (LGE: −20.4±2.2 vs no LGE: −20.1±2.2 vs HV: 19.3±2.0, p=0.6).

### ECG

An abnormal ECG was found in 45.1% of the FD cohort. The frequency of ECG abnormalities was greater in the LVH-positive group compared with the LVH-negative group (75.2% vs 24.7%, respectively). In the total Fabry cohort, ECG abnormalities were associated with a significant impairment in GLS compared with those without ECG abnormalities (abnormal: −16.7±3.5 vs normal: −20.2±2.4, p<0.001). When evaluating the LVH-positive cohort, this same relationship was observed in both males and females. However, in the LVH-negative cohort, only females and not males had a significant difference in GLS with ECG abnormalities (table 4).

### Biomarkers

Of the FD population, 156 (70.6%) had high-sensitivity troponin measured (hsTnT or hsTnl), with 27.6% having an elevated level above centre-specific reference ranges. Median troponin in the total study population was 6.0 μg/L (IQR 1–31 μg/L). An increasing level of troponin was associated with impairment in GLS in the total FD population (r=0.516, p<0.05). Of the LVH-negative population, 87 patients (73.1%) had hsTnT or hsTnl measured and only 5 had an elevated serum level with all others having a value <5 μg/L. No significant relationship was demonstrated between strain and troponin in the LVH-negative group (r=0.169, p=0.118).

### Reproducibility

Intraobserver reproducibility analysis performed following repeat evaluation of 30 CMR scans by observer 1 (RV) demonstrated a mean absolute bias of 0.7±0.6 with an ICC for single measures of 0.98 (95% CI 0.96 to 0.99). Reproducibility biases were similar when assessing interobserver reproducibility following analysis of a subset of 20 CMR scans by observer 2 (BL)—mean absolute bias 0.6±0.5 and ICC for single measures of 0.99 (95% CI 0.97 to 1.0).
in the overall FD cohort, and correlates with myocardial damage as shown by both LGE and biomarker evidence of cell necrosis (troponin), and electrical abnormalities (on the ECG).

2. In LVH-negative FD (early disease), impairment in GLS is associated with a reduction in native T1, suggesting that mechanical dysfunction occurs before the onset of LVH when there is evidence of sphingolipid deposition (low T1). There is a tendency towards a lower GLS in males with early cardiac disease, and females demonstrate no change in GLS until the onset of LVH.

3. In LVH-positive FD, impaired GLS is associated with other signs of overt cardiac involvement, namely increasing LVMI and the presence of LGE.

FD affects the heart. The obvious manifestations have been ECG abnormalities, hypertrophy and, in late stage disease, impairment and thinning.16 17 Biomarkers are also elevated16-20 and valve disease can be present, but the latter is rarely a clinically significant finding. CMR has also identified LGE in early disease, which characteristically affects the basal inferolateral wall. This was initially thought to reflect only fibrosis; however, recent developments using advanced tissue characterisation with CMR parametric mapping (T1 and T2 mapping) has provided further insights. Native T1 is low in FD, representing sphingolipid accumulation21 22 in 85% of FD with LVH, and in up to 59% of LVH-negative patients, suggesting storage occurs early before the establishment of hypertrophy.21 23 When LGE is present without thinning, this has been shown to be associated with T2 elevation and hs-TnT release suggesting an inflammatory process.39 Thus, the order and processes of phenotype development are being pieced together. ECG changes may precede echocardiographic LVH, and latest results suggest there is a pre-LVH phenotype with storage, ECG abnormalities, slight elevation of LV mass and LVEF clustering.9

Here, we introduce a new biomarker of myocardial mechanical dysfunction that is more sensitive than the ejection fraction to early changes in myocardial performance—GLS. This study supports the echocardiographic literature about impaired GLS in overt cardiac involvement in FD (LVH-positive disease), but offers new insights into LVH-negative disease. We have previously shown impaired GLS by speckle tracking echocardiography in a small sample (n=25) of LVH-negative FD with low T1 compared with LVH-negative with normal T1.21 24 This current study expands on these findings by using a much larger cohort and is the first study to assess myocardial strain by CMR in conjunction with T1 mapping to show possible sex differences. It is also the first study to show that ECG abnormalities are associated with impaired GLS—the mechanical and electrical signals are interacting. However, further studies are required to delineate this relationship more clearly.

Sex dimorphism in the FD response to storage has been previously proposed by us in patients with overt disease.3 That is, in addition to apparent faster storage in hemizygous males, LVH-positive males appear to have reduced T1 lowering with increasing LV mass in the LVH range, suggesting the dilution of the T1 lowering sphingolipid signal by the presence of triggered sarcocemic protein. A further example found here is that LGE can be present in LVH-negative females but rarely in males.25 26 Here, there appears to be a trend in the way mechanical dysfunction appears also to have a sex dimorphism with female LVH-negative patients seemingly tolerating storage better than males—females tended to have preserved GLS until the presence of LVH, whereas males had impaired GLS with T1 lowering before the onset of LVH.

The limitations of this study include that it is only a single time point study with no follow-up data, but it is multicentre with a relatively large number of participants for a rare disease. A further limitation is that this study is only evaluating 2D longitudinal strain and not 3D strain. Preliminary results included assessment of 3D circumferential and radial strain, both of which demonstrated similar patterns to 2D GLS. However, when using LV short-axis images to assess 3D strain parameters in FD patients with LVH and cavity obliteration, there was significant impairment in myocardial border tracking, thus excluding a large proportion of the study cohort. Consequently, this study only assessed 2D GLS. Histological validation of T1 mapping for storage is lacking and it is likely that T1 mapping will miss the earliest storage due to the presence of a detection threshold in this technique. Further studies are also required to establish whether early institution of ERT based on a low T1 or impaired GLS in the absence of LVH affects the development of cardiac involvement.

CONCLUSIONS

In FD with LVH, myocardial strain (measured by GLS) reduces with hypertrophy, storage (measured by a low T1), ECG abnormalities and scar (measured by LGE). In early disease (LVH negative), GLS impairs as native T1 reduces.

What is already known on this subject?

► Cardiac involvement in Fabry disease is characterised by progressive left ventricular hypertrophy, myocardial fibrosis and heart failure.

► Impairment of systolic strain measured using speckle-tracking echocardiography has previously been described in Fabry disease.

► Cardiovascular magnetic resonance (CMR) imaging with T1 mapping can identify cardiac involvement earlier in the disease process; however, there are only limited data investigating the relationship between myocardial strain and sphingolipid deposition.

What might this study add?

► This is the first study evaluating T1 mapping and myocardial systolic strain using CMR feature tracking in a large cohort of patients with Fabry disease.

► It shows that there is impairment in myocardial strain as native T1 reduces, highlighting the functional consequences of sphingolipid storage.

How might this impact on clinical practice?

► This study highlights that CMR feature tracking is a sensitive imaging biomarker that is able to identify myocardial mechanical changes in the early stages of cardiac Fabry disease.

Acknowledgements The authors acknowledge the help of Dr James Hodson, Statistician at the Wellcome Trust Clinical Research facility, University Hospital Birmingham NHS Foundation Trust.

Contributors All co-authors contributed to data interpretation and subsequent editing of the manuscript.

Funding This study is part of the Fabryn400 study (NCT03199001), which is funded by an investigator-led research grant from Genzyme.

Competing interests RK has received honoraria from Sanofi-Genzyme.

Patient consent Obtained.
Heart failure and cardiomyopathies

Ethics approval  The study was approved by the relevant Research Ethics Committees and conformed to the principles of the Helsinki Declaration.

Provenance and peer review  Not commissioned; externally peer reviewed.

REFERENCES

1. Zarate YA, Hopkin RJ. Fabry’s disease. The Lancet 2008;372:1427–35.
2. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003;138:338–46.
3. Patel MR, Cecchi F, Cizmarik M, et al. Cardiovascular events in patients with Fabry disease natural history data from the fabry registry. J Am Coll Cardiol 2011;57:1093–9.
4. Weidemann F, Niemann M, Breunig F, et al. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 2009;119:524–9.
5. Costanzo L, Buccheri S, Capranzano P, et al. Early cardiovascular remodelling in Fabry disease. J Inherit Metab Dis 2014;37:109–16.
6. Saccheri MC, Cianciulli TF, Lax JA, et al. Two-dimensional speckle tracking echocardiography for early detection of myocardial damage in young patients with Fabry disease. Echocardiography 2013;30:717–22.
7. Shanks M, Thompson RB, Paterson ID, et al. Systolic and diastolic function assessment in Fabry disease patients using speckle-tracking imaging and comparison with conventional echocardiographic measurements. J Am Soc Echocardiogr 2013;26:1407–14.
8. Morris DA, Blaschke D, Camaan-Kühl S, et al. Global cardiac alterations detected by speckle-tracking echocardiography in Fabry disease: left ventricular, right ventricular, and left atrial dysfunction are common and linked to worse symptomatic status. Int J Cardiovasc Imaging 2015;31:301–13.
9. Nordin S, Kozor R, Bullock H, et al. Cardiac Fabry disease with late gadolinium enhancement is a chronic inflammatory cardiomyopathy. J Am Coll Cardiol 2016;68:1707–8.
10. Tanišlav C, Guenduez D, Liebetrau C, et al. Cardiac troponin I: a valuable biomarker indicating the cardiac involvement in Fabry disease. Circulation 2016;133:929–39.
11. Pica S, Sado DM, Maestrini V, et al. Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2014;16:99.
12. Thompson RB, Chow K, Khan A, et al. T1 mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging 2016;9:637–45.
13. Sado DM, White SK, Piechnik SK, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 2013;6:392–8.
14. Nordin S, Kozor R, Medina-Menacho K, et al. Proposed stages of myocardial phenotype development in Fabry disease. JACC Cardiovasc Imaging 2018. doi: 10.1016/j.jcmg.2018.03.020. [Epub ahead of print 11 May 2018].
15. Moon JC, Sachsdev B, Elkington AG, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003;24:2151–5.
16. Nienmann M, Herrmann S, Hu K, et al. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging 2011;4:592–601.